ArticleDiscover oncology2025
Global research trends and emerging hotspots in nano-drug delivery systems for lung cancer: a comprehensive bibliometric analysis (1998-2024).
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The rising influence of lipid metabolism in lung cancer: a global research perspective.Frontiers in oncology · 2025Pooled it
- Landscape and evolutionary trends of nanotechnology in cancer radiosensitization.Discover nano · 2026Review
- Construction, evaluation, and applications of renal barrier-on-a-chip system.Bioactive materials · 2026Review
- Obovatol induces apoptosis in breast cancer by downregulating the PI3K/Akt pathway.Translational cancer research · 2026Article
- NanoMarine therapeutics: a new wave in drug delivery from oceanic bioresources targeting colon cancer via miRNA modulation.Frontiers in genetics · 2025Review
- Advances in Targeted Engineered Nanoparticle-Based Therapeutics for Respiratory Diseases: Current Insights and Future Perspectives.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNano-drug delivery systems (NDDS) have become a promising alternative and adjunctive strategy for lung cancer (LC) treatment. However, comprehensive bibliometric analyses examining global research efforts on NDDS in LC are scarce. This study aims to fill this gap by identifying key research trends, emerging hotspots, and collaboration networks within the field of NDDS and LC.
methodsA total of 2452 publications, spanning from 1998 to 2024, were extracted from the Web of Science Core Collection. The data were analyzed using tools such as VOSviewer, CiteSpace, and the R package 'bibliometrix'.
resultsThe analysis covered contributions from 12,539 researchers affiliated with 2689 institutions across 55 countries, with their work published in 551 different journals. Research output has increased steadily, with China and the United States leading in both publication volume and impact. Major contributors include the Chinese Academy of Sciences and Shanghai Jiao Tong University. The International Journal of Nanomedicine published the most articles, while Journal of Controlled Release ranked highest in co-citations. Kamal Dua authored the most papers, and Maeda, H. was the most frequently co-cited author. Key research areas encompass "active targeting", "drug delivery optimization", "overcoming drug resistance", "nanocarriers", and "pulmonary drug delivery". Emerging hotspots include "epithelial mesenchymal transition", "mucus penetration", "lipid nanoparticles", "hydrogels", and "immune checkpoint inhibitors".
conclusionThis bibliometric analysis, the first comprehensive study on NDDS in LC, identifies China and the United States as leading contributors in publication volume and impact. Key research areas include "active targeting" and "drug delivery optimization", with emerging hotspots such as "lipid nanoparticles" and "immune checkpoint inhibitors". These findings provide essential insights to guide future research and optimize treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.